We got a new FDA cannabis enforcement memo on Wednesday, April 1, regarding “hemp-derived CBD research in medical research models.” The general thrust is FDA’s assurance that it won’t interfere with a new federal initiative, which covers up to $500 of hemp-derived products for eligible Medicare patients. That initiative is called the Substance Access Beneficiary
Harris Sliwoski LLP attorney Jason Adelstone will be moderating a panel at the upcoming Industrial Hemp International Conference and Trade Show, in Denver, Colorado. Jason will be joined on the panel by attorney David Sergi and political consultant Kevin Lampe. Their session, “Legal Reality Check: Cannabinoids, Compliance, and Enforcement in a Shifting U.S. Landscape,” will
Sine die came for Oregon’s 2026 legislative session last Friday, March 6th. I previewed the roster of cannabis bills in play back on February 12th. Two of them passed; two of them failed. Below is a recap of the action, with links to each bill in the headers. HB 4139 (FAILED) This was the session’s
Most commentary on the “hemp ban” included in the November funding bill has focused on two related questions: (1) which products and activities may become unlawful on November 12, 2026; and (2) whether Congress will materially amend or delay the ban before then. I recently discussed another consequence operators should be considering as the deadline
In the last year or two, we have seen a growing number of marijuana businesses take the position that IRC 280E no longer applies to them. Some of these businesses have taken that position in consultation with lawyers and CPAs. This shift in strategy predates Trump’s Executive Order of December 18, 2025, to reschedule marijuana
Oregon’s 2026 legislative session began last week on February 2. The biennial “short session” will last but 35 days, and focus on budget shortfalls, transportation and housing—which is to say that cannabis is not a priority. That said, of the 300 or so introduced bills, there are four cannabis-related submissions. That’s where I come in.
Earlier this month, the Bailiwick of Jersey appeared poised to take a measured, evidence-based step toward re-examining its approach to non-medical cannabis. Three reform proposals put forward by Tom Binet, Minister for Health and Social Services, were expected to be debated by the States Assembly of Jersey on February 3, 2026. That debate has now
Last month, we hosted a webinar on federal cannabis law and policy in 2026. While things are not where we’d like them to be, it’s amazing to consider everything that has happened over the years. From a lawyering perspective, it’s almost unbelievable. I have worked as a business lawyer in the cannabis industry for over
Most commentary on the “hemp ban” included in the November funding bill has focused on two, related considerations: (1) which products and activities will become unlawful on November 12, 2026, and (2) whether Congress will materially amend, or delay, the ban before then. While that focus is understandable, it overlooks a critical, and more immediate,
U.S. federal cannabis law is at a pivotal moment heading into 2026. In a January 15th webinar, attorneys Jason Adelstone and Vince Sliwoski examined two major federal developments that are poised to reshape the industry: the Executive Order directing the rescheduling of marijuana under the Controlled Substances Act, and new Congressional legislation redefining “hemp,” effective
